11th January 2019, Hyderabad, India: Hetero, one of India’s leading Indian generic pharmaceutical company and the globally biggest manufacturer of anti-retroviral drugs, announce the release of generic version of Lapatinib (250 mg) tablets in India.
It’s used for the treatment of advance or metastatic breast cancer within the country.
The product is advertised and distributed by the brand name ‘HERTAB’ via Hetero Healthcare Ltd.
It’s available in two SKUs, each along with 30 pills and 150 tablets.
HERTAB generic Lapatinib is an oral remedy indicated for the treatment of postmenopausal women with HER2-positive advanced breast cancer patients whose disease has progressed after taking Trastuzumab therapy.
The tablets are utilized along with with Capecitabine or Letrozole, which collectively, inhibit the growth of cancer cells in patients, Hetero stated.
Natco Generic Lapatinib (Herduo)
Natco pharma, India’s of the leading generic manufacturer also have the generic version of Lapatinib with the brand name of Herduo 250 mg tablets.